RecruitingEarly Phase 1NCT06171152

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Examining the Utility of GLP-1 Agonists as Neuroprotective Agents Through a Pilot Clinical Trial in High Risk Population With Neurocognitive Deficits and Obesity

Sponsor

University of Chicago

Enrollment

30 participants

Start Date

Jan 26, 2024

Study Type

INTERVENTIONAL

Conditions

Obesity Multiple Sclerosis Long COVID Long Covid19 Obese Obesity, Morbid Acute Leukemia in Remission

Summary

This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life. By doing this study, researchers hope to learn how liraglutide (Saxenda®), a weight loss drug, affects levels of a certain disease marker in the body called Brain Derived Neurotrophic Factor (BDNF). Participation in this research will last about 21 weeks.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether liraglutide — a medication used for weight loss — can improve memory and cognitive (thinking) problems in young adults with obesity who have MS, long COVID, or leukemia in remission. **You may be eligible if...** - You are between 18 and 39 years old - You have multiple sclerosis (MS), long COVID, or acute leukemia that has been in remission for at least 6 months - You have subjective cognitive problems (feeling like your memory or thinking is off) - Your BMI is 30 or above, OR your BMI is 27 or above with a weight-related condition like high blood pressure, insulin resistance, or high cholesterol - Your kidney and liver function are within acceptable levels **You may NOT be eligible if...** - You are pregnant, planning to become pregnant, or not willing to use contraception - You have had major surgery or radiation within the last 2 months - You have serious organ dysfunction Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLiraglutide Pen Injector [Saxenda]

A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.

OTHERMedication Diary

Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.